The Importance Of Scalability In Viral Vectors

Eva Fong Feature
Eva Fong, Senior Scientist, MilliporeSigma

Gene therapy has the potential to change countless patients’ lives. Diseases that lacked cures or even treatments may be addressed with these new classes of therapeutics. This potential has spurred new investments in the drug development and commercialization space.

Viral vectors are often challenging to produce, especially at the large scales needed to reach the potential of these therapies. The manufacturing process for gene and cell therapies is complex and the current scale-out approach does not support robust industrialization. By developing a process with scale-up capabilities early on, you can address both clinical and commercial needs. This will minimize unnecessary process changes and the comparability studies required to demonstrate product equivalence.

In this article, we’ll dive deep into the importance of scalability in viral vectors with Eva Fong, Senior Scientist at MilliporeSigma.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene